Department of Orthopaedics, Shandong Provincial Hospital affiliated to Shandong University, No.324, Road Jing Wu Wei Qi, Jinan, 250021, Shandong, China.
Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, University Hospital of Munich (LMU), Campus Grosshadern, Marchioninistrasse 23, 81377, Munich, Germany.
BMC Cancer. 2019 Apr 5;19(1):323. doi: 10.1186/s12885-019-5488-5.
Multiple trials have attempted to assess the diagnostic value of F-fluorodeoxyglucose positron emission tomography/computed tomography (F-FDG PET/CT) in osteosarcoma with results remaining inconclusive. This study aims to investigate the effectiveness of F-FDG PET and PET/CT in the diagnosis, staging, recurrence and metastasis formation observations of osteosarcoma through systematic review followed by meta-analysis.
Three electronic databases, Medline/PubMed, Embase and the Cochrane Library were utilized in this study. Eligible studies that assessed the performance of F-FDG PET/CT for the diagnosis, staging, restaging and recurrence monitoring of osteosarcoma were retrieved utilizing specific search criteria. After screening and diluting out the non-conforming articles, all relevant articles and their data were identified and extracted to calculate the summary metrics involving sensitivity, specificity, diagnostic odd ratio (DOR), and area under the curve (AUC) to determine the effectiveness of F-FDG PET in diagnosing osteosarcoma clinically.
Out of 1976 articles searched, twenty-six studies were identified that were viable. All data from these articles, utilized in the quantitative analyses, showed after meta-analysis that when utilizing F-FDG PET or PET/CT it was better with a success rate of 90-100% for detecting primary lesions and distant metastases of patients with osteosarcoma. Similar results were also obtained for detecting lung and bone metastases in a subgroup analysis.
As such the investigation demonstrated that F-FDG PET and PET/CT are very accurate for the diagnosis, staging and recurrence monitoring of osteosarcoma. F-FDG-avid lesions should be further examined in osteosarcoma, especially for suspicious lung lesions.
多项试验尝试评估 F-氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(F-FDG PET/CT)在骨肉瘤中的诊断价值,但结果仍不确定。本研究旨在通过系统评价和荟萃分析,调查 F-FDG PET 和 PET/CT 在骨肉瘤诊断、分期、复发和转移形成观察中的有效性。
本研究使用了三个电子数据库,即 Medline/PubMed、Embase 和 Cochrane 图书馆。使用特定的搜索标准检索评估 F-FDG PET/CT 用于骨肉瘤诊断、分期、再分期和复发监测的性能的合格研究。在筛选和淘汰不符合要求的文章后,确定并提取所有相关文章及其数据,以计算包括敏感性、特异性、诊断优势比(DOR)和曲线下面积(AUC)在内的汇总指标,以确定 F-FDG PET 在临床上诊断骨肉瘤的有效性。
在搜索到的 1976 篇文章中,有 26 篇被确定为可行研究。这些文章中的所有数据都用于定量分析,荟萃分析后显示,在检测骨肉瘤患者的原发性病变和远处转移时,使用 F-FDG PET 或 PET/CT 的成功率为 90-100%。在亚组分析中,也获得了类似的检测肺和骨转移的结果。
因此,研究表明 F-FDG PET 和 PET/CT 非常准确,可用于骨肉瘤的诊断、分期和复发监测。在骨肉瘤中,应进一步检查 F-FDG 阳性病变,特别是可疑的肺部病变。